Nebulcort (Flunisolide)

Flunisolide, the active ingredient in Nebulcort, is a corticosteroid (glucocorticoid) presented as an inhalation formulation for inhalation use. It reduces airway inflammation and is indicated for the management of asthma and allergic rhinitis in patients requiring anti‑inflammatory therapy.

GNH USA supplies Nebulcort as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to EU GMP standards and provides reliable sourcing for respiratory care products across global markets, including bulk shipments and regulatory support for importers.

Flunisolide, an inhaled corticosteroid, targets airway inflammation in respiratory disorders.

Asthma: reduces airway hyper‑responsiveness, decreases frequency of symptoms, and improves lung function in patients with persistent disease. Allergic rhinitis: lessens nasal congestion, sneezing, and itching by decreasing inflammatory mediators in the nasal mucosa. Exercise‑induced bronchospasm: provides prophylactic anti‑inflammatory protection that helps prevent bronchoconstriction triggered by physical activity. COPD (as adjunct therapy): may reduce exacerbation frequency and improve symptom control when combined with bronchodilators in patients with an inflammatory component.

Common Side Effects: - Oral thrush or candidiasis: fungal growth in the mouth due to local immunosuppression. - Hoarseness or dysphonia: irritation of the vocal cords after inhalation. - Throat irritation or cough: local irritation of the oropharyngeal mucosa.

Serious or Rare Side Effects: - Adrenal suppression: reduced endogenous cortisol production with prolonged high‑dose use. - Growth retardation in children: potential impact on linear growth with long‑term therapy. - Severe allergic reaction: anaphylaxis or angioedema requiring immediate medical attention.

Precautions should be observed when prescribing or dispensing Nebulcort.

Assess adrenal function: monitor for signs of systemic glucocorticoid effect during long‑term therapy. Use spacer device: reduce oropharyngeal deposition and lower risk of local side effects. Avoid abrupt discontinuation: taper the dose if therapy has been prolonged to prevent adrenal insufficiency. Pregnancy and lactation: consult a healthcare professional because safety data are limited. Monitor growth in children: perform periodic height assessments during chronic use. Store at room temperature below 25°C: keep in the original container, protect from moisture and direct sunlight.

Nebulcort may interact with other medicines; awareness of interaction severity is important.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors: may increase systemic exposure to flunisolide. - Systemic CYP3A4 inducers: may reduce therapeutic effect. - Concurrent use of multiple inhaled corticosteroids: risk of excess glucocorticoid effects.

Moderate Interactions (Monitor Closely): - Azole antifungals (e.g., ketoconazole): may modestly raise flunisolide levels. - Protease inhibitors (e.g., ritonavir): may increase systemic exposure requiring dose adjustment.